Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 871-878

  Lai, Ming Wei ^a,b   Chen, Tse Ching ^c   Pang, See Tong ^c   Yeh, Chau Ting ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b Chang Gung Children Hospital   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Caspase 3; Cyclin dependent kinase associated protein phosphatase; Renal cell carcinoma; Xenograft tumor

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE ASSOCIATED PROTEIN PHOSPHATASE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURGERY; CARCINOGENICITY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOPLASM; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; GROWTH RATE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; TRANSFECTION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870541520     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.09.010     Document Type: Article

References (34)

1. Brown N.R., Noble M.E.M., Lawrie A.M., et al. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J Biol Chem 1999, 274:8746-8756.
2. Solomon M.J. Activation of the various cyclin/cdc2 protein kinases. Curr Opin Cell Biol 1993, 5:180-186.
3. Atherton-Fessler S., Hannig G., Piwnica-Worms H. Reversible tyrosine phosphorylation and cell cycle control. Semin Cell Biol 1993, 4:433-442.
4. Den Haese G., Walworth N., Carr A., et al. The wee1 protein kinase regulates T14 phosphorylation of fission yeast cdc2. Mol Biol Cell 1995, 6:371-385.
5. Coleman T.R., Dunphy W.G. Cdc2 regulatory factors. Curr Opin Cell Biol 1994, 6:877-882.
6. Kaldis P., Sutton A., Solomon M.J. The cdk-activating kinase (cak) from budding yeast. Cell 1996, 86:553-564.
7. Nigg E.A. Cyclin-dependent kinase 7: At the cross-roads of transcription, DNA repair, and cell cycle control?. Curr Opin Cell Biol 1996, 8:312-317.
8. Lew D.J., Kornbluth S. Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 1996, 8:795-804.
9. Poon R.Y.C., Hunter T. Dephosphorylation of cdk2 thr160 by the cyclin-dependent kinase-interacting phosphatase kap in the absence of cyclin. Science 1995, 270:90-93.
10. Gyuris J., Golemis E., Chertkov H., et al. Cdi1, a human G1 and S phase protein phosphatase that associates with cdk2. Cell 1993, 75:791-803.
11. Hannon G.J., Casso D., Beach D. Kap: A dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci U S A 1994, 91:1731-1735.
12. Song H., Hanlon N., Brown N.R., et al. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphocdk2. Mol Cell 2001, 7:615-626.
13. Lee S.W., Reimer C.L., Fang L., et al. Overexpression of kinase-associated phosphatase (kap) in breast and prostate cancer and inhibition of the transformed phenotype by antisense kap expression. Mol Cell Biol 2000, 20:1723-1732.
14. Yeh C.T., Lu S.C., Chen T.C., et al. Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res 2000, 60:4697-4700.
15. Yeh C.T., Lu S.C., Chao C.H., et al. Abolishment of the interaction between cyclin-dependent kinase 2 and cdk-associated protein phosphatase by a truncated kap mutant. Biochem Biophys Res Commun 2003, 305:311-314.
16. Yu Y., Jiang X., Schoch B.S., et al. Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase kap increases proliferation and migration in glioblastoma. Cancer Res 2007, 67:130-138.
17. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
18. Kessler O., Mukamel E., Gillon G., et al. Effect of improved diagnosis of renal cell carcinoma on the course of the disease. J Surg Oncol 1994, 57:201-204.
19. Neumann H.P.H., Zbar B. Renal cysts, renal cancer, and von Hippel-Lindau disease. Kidney Int 1997, 51:16-26.
20. Denton M.D., Magee C.C., Ovuworie C., et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: A pathologic analysis. Kidney Int 2002, 61:2201-2209.
21. Amin M., Corless C., Renshaw A., et al. Papillary (chromophil) renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 1997, 21:621-635.
22. McCredie M., Stewart J.H. Risk factors for kidney cancer in New South Wales. IV. Occupation. Br J Ind Med 1993, 50:349-354.
23. Lam J., Belldegrun A., Pantuck A. Long-term outcomes of the surgical management of renal cell carcinoma. World J Urol 2006, 24:255-266.
24. Kovacs G., Akhtar M., Beckwith B., et al. The Heidelberg classification of renal cell tumours. J pathol 1999, 183:131-133.
25. Goldstein N.S. Grading of renal cell carcinoma. Urol Clin North Am 1999, 6:637-642.
26. Pantuck A.J., Zeng G., Belldegrun A.S., et al. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma. Clin Cancer Res 2003, 9:4641-4652.
27. Hambor J.E., Hauer C.A., Shu H.K., et al. Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic t-cell clone. Proc Natl Acad Sci U S A 1988, 85:4010-4014.
28. Yeh C.T., Lai H.Y., Chen T.C., et al. Identification of a hepatic factor capable of supporting hepatitis c virus replication in a nonpermissive cell line. J Virol 2001, 75:11017-11024.
29. Yeh C.T., Lu S.C., Tseng I.C., et al. Antisense overexpression of BMAL2 enhances cell proliferation. Oncogene 2003, 22:5306-5314.
30. Nelson G.O., Juan R. Kidney, renal pelvis and ureter, bladder. Rosai and Ackerman's surgical pathology 2004, 1261. Mosby, Missouri. 9th ed. J. Rosai (Ed.).
31. Janzen N.K., Kim H.L., Figlin R.A., et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843-852.
32. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
33. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
34. Grandinetti C., Goldspiel B. Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer. Pharmacotherapy 2007, 27:1125-1144.